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Abstract The phosphorylation and desensitization of metabo-
tropic glutamate receptor type 1c in response to agonist and
phorbol esters has been studied. Specific immunoprecipitation of
mGluR1c from cells treated with agonist or PMA showed a time-
dependent increase in the phosphorylation of a membrane protein
with the same molecular weight as the dimeric form of the
receptor. Measurements of inositol phosphate production showed
a rapid functional desensitization of about 90% after agonist
treatment, whereas treatment with PMA caused only a 30% loss
in the same time. The extent of receptor phosphorylation
following the different treatments paralleled the desensitization
of the receptor. These results strongly suggest that phosphoryla-
tion of the dimeric form of mGluR1c, as a functionally active
form, may play a role in its rapid desensitization.
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1. Introduction
Glutamate is the major excitatory neurotransmitter in the
mammalian brain and acts at multiple receptor types. These
receptors can be divided into two groups namely the iono-
tropic receptors, which form ion channels, and metabotropic
receptors coupled by G-proteins to various second messengers
systems [1]. Eight members of the mGluRs family have been
identi¢ed and categorized into three subgroups on the basis of
their sequence homology, agonist selectivity and signal trans-
duction pathway. Group I contains mGluRs 1 and 5, which
are coupled to phospholipase C in transfected cells, and quis-
qualic acid (Quis) is their most potent agonist. Five splice
variants of mGluR1 have been described, namely metabo-
tropic glutamate receptor (mGluR)1K, mGluR1L, mGluR1c,
mGluR1d and mGluR1e [1,2], all of them di¡ering in the
length of the C terminal tail.
G-protein-coupled receptors (GPCRs) undergo homologous
[3] and heterologous desensitization [4]. In the former the
receptor loses its responsiveness to a subsequent stimulation
after activation by its agonist, in the latter responsiveness is
lost after activation of a di¡erent receptor or cell signalling
pathway. Receptor desensitization is a complex process which
can involve phosphorylation of the molecule, its uncoupling
from G-proteins, its internalization/sequestration, and ulti-
mately its down-regulation. In the well-characterized L2-ad-
renergic system, desensitization involves phosphorylation of
some serine-threonine residues of the receptor by two di¡erent
mechanisms. On the basis of these studies, it has been sug-
gested that after a short period of agonist exposure, the re-
ceptors uncouple from G proteins due to phosphorylation
catalyzed by receptor-speci¢c kinases (e.g. L-adrenergic recep-
tor-associated kinase-1 and -2) and/or kinases regulated by
second messengers (e.g. PKA and PKC). Phosphorylation of
the receptor by kinases increases the a⁄nity of the receptor
for cytosolic factors (arrestins and adapters) that impairs the
ability of the receptor to interact with G proteins [5].
In this study we have examined the phosphorylation and
desensitization of mGluR1c in response to Quis and PMA
treatment, using a permanently transfected CHO-K1 cell
line. Phosphorylation was measured using speci¢c monoclonal
antibodies against phospho-serine and by 32Pi metabolic label-
ling of CHO-K1 cells, as described previously [6]. The time
course desensitization was determined by agonist inositol
phosphate generation after preincubation with Quis or
PMA. Together, these approaches have allowed us to delin-
eate the kinetics of regulation of mGluR1c permanently ex-
pressed in Chinese hamster ovary cells.
2. Materials and methods
2.1. Antibodies
The F1 serum was raised against a histidine tagged fusion protein
containing an amino terminal sequence of mGluR1, residues 121^341
[7]. Puri¢ed anti-phosphoserine (clone 1C8) monoclonal antibody was
purchased from BIOMOL (Hamburg, Germany) and used as de-
scribed before [6]. Monoclonal anti-L-tubulin clone TUB 2.1 was ob-
tained from Sigma. Fluorescein (FITC)-conjugate a⁄nity puri¢ed
donkey anti-rabbit IgG was from Jackson ImmunoResearch Labora-
tories, Horseradish-peroxidase(HRP)-conjugate swine anti-rabbit IgG
and HRP-conjugate swine anti-mouse IgG were from Dako. Horse-
radish-peroxidase(HRP)-conjugate rabbit anti-mouse IgM was from
Sigma.
2.2. Cell culture, membrane preparation and protein determination
CHO-K1 cells were transfected with an in-house expression vector
encoding the rat mGluR1c and the resistance marker aminoglycoside
phosphotransferase (neor) under control of the single CMV promoter.
The continued presence of Geneticin G-418 in the culture medium was
essential to select and to maintain the positive clones. CHO-K1 per-
manently transfected with mGluR1c were grown at 37‡C in 5% CO2
in Dulbecco’s modi¢ed Eagle medium (DMEM, Sigma) supplemented
with 7.5% decomplemented dialyzed fetal bovine serum, 1 mM gluta-
mine, 0.3 mM proline, 4.5 g/l glucose and 500 Wg/ml Geneticin G-418.
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Before incubation with any drug, cells were grown in glutamate-free
medium (ICN) in the absence of both glutamine and glutamic acid for
3 h.
Membranes of cells were prepared by shearing them in 10 mM
NaHCO3 as previously described [7] and protein was measured by
the bicinchoninic acid method.
2.3. SDS/PAGE, immunoblotting and immunoprecipitation
Cell membranes were treated with SDS-PAGE sample bu¡er [7],
before loading onto the polyacrylamide gels. Electrophoresis was per-
formed using 6% polyacrylamide gels [8]. Proteins were transferred to
polyvinylidene £uoride (PVDF) membranes (Immobilon-P, Milli-
pore), using a semi-dry transfer system bu¡er [7] and immunoblotted
using anti-mGluR1 a⁄nity puri¢ed F1 antibody (F1-Ab; 2^4 Wg/ml)
[9]. For immunoblotting with anti-phosphoserine antibody clone 1C8
cells were ¢rst immunoprecipitated with F1-Ab and then immunoblot-
ted as described previously [6]. Immunoreactive bands were detected
with HRP-conjugated anti-rabbit (1:5000), anti-mouse (1:5000) and/
or anti-mouse IgM (1:2000) followed by chemiluminescence detection
(Pierce).
2.4. Biotinylation of cell surface proteins
Biotinylation was performed as described previously [10] using 50
Wg/ml sulfo-NHS-LC-biotin (Pierce) in borate bu¡er for 5 min at
room temperature. Biotinylated cell surface proteins were isolated
using Streptavidin-agarose beads and immunoblotted as described
above.
2.5. mGluR1c phosphorylation
Whole cell phosphorylation studies were carried out in a manner
similar to that described previously [6,11]. Brie£y, CHO-K1 cells per-
manently transfected with mGluR1c were incubated with
[32P]orthophosphate (1 mCi/ml) for 4 h at 37‡C in 5% CO2 in phos-
phate/glutamine-free medium. The cells were then incubated for the
indicated times with the medium alone or the medium plus the indi-
cated concentrations of PMA or the agonist Quis, washed three times
with ice-cold phosphate-bu¡ered saline (PBS), and scraped in ice-cold
lysis bu¡er for 1 h on ice. The solubilized preparation was then cen-
trifuged at 80 000Ug for 90 min. The supernatant was processed for
immunoprecipitation as described above. Immune complexes were
dissociated by heating to 100‡C for 5 min and resolved by SDS-poly-
acrylamide gel electrophoresis in 6% gels. The gels were run, dried and
autoradiographed.
2.6. Inositol phosphate (IP) accumulation
CHO-K1 cells permanently transfected with mGluR1c were grown
(overnight) in glutamine/inositol-free medium (DMEM supplemented
with 7.5% fetal bovine serum, dialyzed against inositol-free DMEM)
containing myo-[3H]inositol (5 WCi/ml; Amersham, UK). Washed
cells, subsequently incubated with the indicated reagents, were col-
lected, washed exhaustively in pre-warmed (37‡C) 4-(2-hydroxyeth-
yl)-1-piperazineethanesulfonic acid (HEPES) bu¡ered Kreb’s solution
(20 mM HEPES, pH 7.4; 145 mM NaCl; 5 mM KCl; 1.2 mM CaCl2 ;
1.3 mM MgCl2 ; 1.2 mM NaH2PO4 and 10 mM glucose) and incu-
bated (106/0.2 ml of PBS) containing 10 mM LiCl for 10 min. Phos-
phoinositide hydrolysis was initiated by the addition of 0.1 ml of pre-
warmed HEPES/Kreb’s containing the indicated Quis concentration.
The total IP pool was measured as described previously [9]. The EC50
of agonist induced IP accumulation was determined by non-linear
regression as described previously [6].
3. Results
In a solubilized fraction prepared from a CHO-K1 cell line
permanently transfected with mGluR1c, the F1 antibody [7]
consistently immunoblotted two major immunoreactive pro-
teins of apparent molecular weight of 94 kDa and 190 kDa
(Fig. 1, lysate). The lower of these molecular weights corre-
sponds to that expected for the receptor and whilst the higher
molecular weight is approximately twice that of the lower,
suggesting the existence of an SDS-resistant dimeric species
of the receptor. These results are in good agreement with
previously reported studies using transiently transfected
HEK cells [12] and with the results obtained with other anti-
bodies to these receptors [7,11]. In order to di¡erentiate which
form of the receptor was present in the plasma membrane, we
performed cell surface protein biotinylation and subsequent
streptavidin isolation (Fig. 1) of the biotinylated cell surface
proteins. Under these conditions, the dimeric form of the
receptor was the dominant form found in the streptavidin
isolated proteins, where often none of the monomeric form
could be detected (Fig. 1, streptavidin). No tubulin could be
detected in the streptavidin isolated, showing that the biotin
ester had not penetrated the cell membrane (Fig. 1, inset pan-
el).
CHO-K1 cells permanently transfected with mGluR1c were
metabolically labeled with 32P and phosphorylation was in-
duced by a 5 or 45 min treatment with 100 WM Quis (agonist)
or 100 nM PMA (protein kinase C activator). Following the
incubation, mGluR1c molecules were immunoprecipitated us-
ing the a⁄nity-puri¢ed speci¢c anti-mGluR1 F1 antibody.
The immunoprecipitate from untreated cells, analyzed by
SDS-PAGE and autoradiography, gave rise to a major phos-
phorylated band of around 190 kDa, similar in size to the
dimeric form of the receptor (compare Fig. 1 with Fig. 2A,
lane 1). Under similar conditions, Quis induced a rapid time-
dependent increase in the phosphorylation of the dimeric form
of the receptor together with a small increment in the phos-
phorylation of a 94 kDa protein, probably corresponding to
the monomeric form of the receptor (Fig. 2A). Phosphoryla-
tion of mGluR1c was also observed when cells were treated
with PMA, showing a smaller but more sustained phosphor-
ylation of the receptor (Fig. 2A). Immunoprecipitates from
agonist or PMA treated cells were also analyzed by immuno-
blotting using a monoclonal antibody against phospho-serine
residues (see Section 2). Using this, stimulation of CHO-K1
cells with Quis led to a rapid time-dependent phosphorylation
Fig. 1. Cell surface biotinylation of mGluR1c permanently expressed
in CHO-K1 cells. CHO-K1 cells permanently transfected with
mGluR1c were cell surface biotinylated by incubation with 50 Wg/ml
of sulfo-NHS-LC-biotin in borate bu¡er as described in Section 2.
The labelled proteins were isolated with streptavidin-agarose beads
and complexes were applied to 6% SDS-PAGE gels (streptavidin
lane) to be analyzed by immunoblotting using a polyclonal anti-
mGluR1 a⁄nity puri¢ed F1 antibody (2^4 Wg/ml) or a monoclonal
anti-L-tubulin (1:200) (inset panel). A portion of solubilized extract
was analyzed by SDS-PAGE and immunoblotted under the same
conditions (lysate lane). Immunoreactive bands were detected with a
swine anti-rabbit (1:5000) or a swine anti-mouse (1:5000) secondary
antibody conjugated to horseradish peroxidase followed by chemilu-
minescence detection.
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of the receptor again mainly in its dimeric form (Fig. 2B), in
agreement with the results previously obtained using 32Pi (Fig.
2A). A similar time course for the phosphorylation of the
dimeric form of mGluR1c following stimulation with PMA
was also observed using the anti-phosphoserine antibodies
(Fig. 2B). It should be noted that re-probing the anti-phos-
phoserine blots with the mGluR1 F1 antibody gave an immu-
noreactive band which overlaid that visualized by the former,
con¢rming that indeed the 190 kDa protein contained
mGluR1c and was most probably the dimeric form of the
receptor.
In order to characterize the protein kinase involved in this
rapid and transient phosphorylation of mGluR1c permanently
expressed in CHO-K1 cells, we analyzed the phosphorylation
level of mGluR1c after 5 min of exposure to stimuli in the
presence or absence of the speci¢c protein kinase C inhibitor
Ro318220 (Fig. 3). Under these conditions, we found that the
degree of basal phosphorylation of the dimeric form of
mGluR1c is diminished in the presence of the inhibitor, sug-
gesting a role for PKC in the basal phosphorylation level of
mGluR1c. When the cells were stimulated with agonist for
5 min, Ro318220 only partially inhibited the agonist induced
phosphorylation. Finally, when cells were stimulated with
PMA, the PKC inhibitor totally blocked the receptor phos-
phorylation (Fig. 3). These results suggest the existence of a
protein kinase other than protein kinase C producing the
rapid agonist mediated phosphorylation.
Experiments of second messenger production were carried
out to analyze the e¡ect of phosphorylation on signalling via
mGluR1c. In CHO-K1 cells permanently transfected with
mGluR1c, the full agonist Quis increased the level of IP
with an EC50 of 1.3 þ 0.6 WM (Fig. 4A).
Cells were pretreated with 100 WM Quis or 100 nM PMA
for 5 min, extensively washed to eliminate the excess of the
reagents and re-stimulated with 100 WM Quis in HBSS/Krebs
bu¡er containing 10 mM LiCl for 5, 15 and 45 min. The
responsiveness of treated cells was compared with cells prein-
cubated with bu¡er alone. Under these conditions, pretreat-
ment of cells with agonist causes a maximal desensitization
(V90%) of mGluR1c responsiveness at the earliest time point
studied (5 min) followed by a recovery to nearly normal levels
after 45 min. When PMA induced desensitization was ana-
lyzed, we observed that it also was maximal following a
5 min treatment but caused only a loss of 20% of mGluR1c
maximal responsiveness. The time-course of agonist and PMA
desensitization correlate well with the time-course of agonist
and PMA induced receptor phosphorylation, suggesting a re-
lationship between short term phosphorylation of mGluR1c
and short term desensitization of the receptor (Fig. 4B)
Next, we analyzed the e¡ect of Ro318220 on the PMA and
agonist short time induced desensitization. In control CHO-
K1 cells permanently expressing mGluR1c a 10 min pretreat-
ment of cells with Ro318220 before the agonist stimulation,
induced an increment of 50% in the total IP production when
compared with non-pretreated cells. However, agonist in-
duced desensitization of 90 þ 5% was minimally a¡ected by
the speci¢c PKC inhibitor remaining at 70 þ 10%. On the oth-
Fig. 2. Phosphorylation of mGluR1c. A: Phosphorylation as deter-
mined by 32P metabolic labelling. CHO-K1 cells permanently trans-
fected with mGluR1c were metabolically labelled with
[32P]orthophosphate as described in Section 2. After washing, cells
were treated with 100 WM Quis or 100 nM PMA for 5, or for 45
min, and the receptor was isolated by immunoprecipitation with
anti-mGluR1 a⁄nity puri¢ed F1 antibody (5 Wg/ml), applied to 6%
SDS-PAGE gels and autoradiographed. B: Phosphorylation as de-
termined by immunoblotting using anti-phospho-serine antibodies.
CHO-K1 cells permanently transfected with mGluR1c were stimu-
lated with 100 WM Quis or 100 nM PMA for 5, or for 45 min and
then processed for immunoprecipitation using the anti-mGluR1 af-
¢nity puri¢ed F1 antibody (5 Wg/ml). The immunocomplexes were
separated in a 6% SDS-PAGE gel and then immunoblotted using
an anti-phospho-serine antibody clone 1C8 as described in Section
2.
Fig. 3. Characterization of the protein kinase involved in the
mGluR1c phosphorylation. CHO-K1 cells permanently transfected
with mGluR1c were preincubated in absence or presence of 100 nM
Ro318220 during 10 min and then stimulated with 100 WM Quis or
100 nM PMA during 5 min. Cells were processed for immunopre-
cipitation using the anti-mGluR1 a⁄nity puri¢ed F1 antibody (5
Wg/ml) and the immunocomplexes were analyzed as described be-
fore. The immunoreactive dimer band on the X-ray ¢lm was meas-
ured by densitometric scanning and plotted on the upper panel. The
results are the mean þ S.E.M. of three independent quanti¢cations.
*, P6 0.01 when compared with unstimulated cells.
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er hand, the small desensitization of mGluR1c IP generation
induced by PMA alone of 20 þ 8% was entirely blocked by
pretreatment of the cells with 100 nM Ro318220 (Fig. 4C).
These results show that the PMA induced desensitization of
mGluR1c is mediated by PKC, whereas the agonist induced
desensitization of mGluR1c is mainly mediated by another
protein kinase.
4. Discussion
Recently, evidence has emerged that the seven transmem-
brane GPCRs may be present as dimers in the plasma mem-
brane. To date several GPCRs have been shown to form
dimers when expressed in mammalian cells, namely the L-
adrenergic receptor [13], the D2 dopamine receptor [14], the
opioid receptor [15], the adenosine A1 receptor [16] and
mGluR5 [17]. The precise function of GPCR dimerization
has not been fully elucidated, for example the L-adrenergic
receptor dimerization is important for e⁄cient receptor G-
protein coupling [13], whereas for the opioid receptor homo-
dimerization seems to have a role in the regulation of receptor
internalization [15].
In the case of mGluRs group I, they appear to be disul¢de
bonded dimers with the N-terminal domain containing the
residues responsible for their dimerization [17,18]. Here we
show that mGluR1c appears to be preferentially isolated
from biotinylated cells as an SDS-resistant dimer. Similar re-
sults were also obtained following cell surface biotinylation of
the other short C-terminal subtype of mGluR1, mGluR1L
[10]. Since the N-terminal domain of mGluR1K alone forms
a disul¢de bonded dimer [18] it is likely that both mGluR1L
and mGluR1c will be similarly bonded and dimeric. The fail-
ure of the mGluR1L and mGluR1c dimers to dissociate in
SDS-sample bu¡er even in the presence of reducing agents
may be due to their lack of the large C-terminal domain
found in mGluR1K. The absence of this domain could permit
strong hydrophobic interactions between the transmembrane
domains following receptor solubilization resulting in SDS-
resistant dimer formation. The small amount of monomeric
mGluR1c found in the total cell extracts may re£ect the pres-
ence inside the cell of non-dimerized receptor.
Agonist stimulated phosphorylation of GPCRs plays a cen-
tral regulatory role in transmembrane signalling [3,5]. Studies
on the phosphorylation of GPCRs have found correlation
between functional desensitization and receptor phosphoryla-
tion including phospholipase C-coupled receptors (e.g. the
m1-muscarinic receptors [19], the adenosine A1 receptor [6],
the neurokinin 2 receptor [20], the platelet activating factor
receptor [21] and the K1B-adrenergic receptor [22]). mGluR1c
is phosphorylated following agonist and PMA treatment with
a time course that was consistent with an involvement in
receptor desensitization. The phosphorylation was transient,
being rapidly reversed and diminishing to nearly basal levels
after treatment with PMA, and to basal levels following ex-
posure to agonist after 45 min. Previously. we have shown
that mGluR1K expressed in BHK cells, undergoes a similar
rapid and reversible phosphorylation following exposure to
Quis [11]. Similar time-courses of phosphorylation following
agonist treatment has been described for other G-protein
coupled receptors (e.g. the cholecystokinin receptor [23]).
There is considerable evidence to show that the group I
mGluRs undergo a rapid desensitization following agonist
treatment and that protein kinase C may be implicated in
this process. Thus, the treatment of synaptosomes, brain slices
or cultured cerebellar granule cells with protein kinase C ac-
tivators results in either the complete or partial abolition of
agonist responses [24^27]. The di¡erences reported in these
studies between the total or partial inhibition of agonist re-
sponses following phorbol ester treatment, may re£ect the
varying levels of expression of mGluR1 and mGluR5 in the
di¡erent brain areas used for experimentation. In addition,
the presence of multiple receptor subtypes in these prepara-
tions makes a comparison of these results with ours, obtained
using a single cell type and one receptor subtype, di⁄cult.
Nevertheless, we have observed a partial inhibition of agonist
responses following phorbol ester treatment of the CHO cells
Fig. 4. Functional characterization of mGluR1c permanently ex-
pressed in CHO-K1 cells. A: concentration dependence of IP gener-
ation in response to Quis stimulation. Cells were stimulated with
varying concentrations of Quis during 20 min. IP generations were
determined as described in Section 2. Values are expressed as fold-
increment in the IP production over the baseline (non-stimulated
cells). The EC50 was determined by non-linear regression (see Sec-
tion 2). B: Time-course desensitization of IP generation to Quis.
The time course of desensitization after exposure of cells to 100 WM
Quis (¢lled square) or 100 nM PMA (¢lled circle) is shown. After
5 min pretreatment, the cells were extensively washed to eliminate
the excess of agonist or PMA and re-stimulated with 100 WM Quis
during 5, 15 and 45 min. C: The e¡ect Ro318220 on short time
(5 min) mGluR1c induced desensitization. Cells were preincubated
in absence or presence of 100 nM Ro318220 for 10 min before the
Quis or PMA stimulation. IPs were isolated as indicated in Section
2. Data are plotted as mean þ S.E.M. values of quintuplicate deter-
minations. *, P6 0.01 when compared with unstimulated cells.
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expressing mGluR1c and rapid and full densensitization fol-
lowing agonist application.
It is interesting to note that two types of protein kinase,
di¡erentiated by their sensitivity to the highly speci¢c PKC
inhibitor Ro318220, appear to phosphorylate mGluR1c. Thus
whilst PKC may have a role in the desensitization of
mGluR1c another protein kinase(s), possibly one of the G-
protein coupled receptor kinases, whose existence in CHO-K1
cells has been demonstrated [28], may be responsible for the
majority of the rapid agonist mediated desensitization of
mGluR1c in this cell line. In this context it is interesting to
note that in other studies of the agonist response of cells
permanently transfected with mGluR1K, pretreatment of the
cells with phorbol esters only partially abolished their agonist
mediated IP responses as seen for mGluR1c in this study
[29,30]. In BHK cells permanently expressing mGluR1K the
basal level of receptor phosphorylation was signi¢cantly high-
er than that seen for mGluR1c in this study [11]. Pretreatment
of the BHK cells prior to agonist treatment with the speci¢c
protein kinase inhibitor, Ro318220, reduced the basal level of
mGluR1K phosphorylation but did not prevent it, suggesting
that a kinase other than PKC might be involved in its phos-
phorylation [11]. Whilst bearing in mind the caveat that re-
combinant receptors expressed in cell lines lack many of the
regulatory elements that would normally exist in their normal
cell environment these results suggest that kinases other than
protein kinase C may be involved in the desensitization of the
Group I mGluRs. The relative importance of protein kinase C
in their desensitization may vary with the subtype of the re-
ceptor and/or the cell type in which it is expressed.
In conclusion, the results presented here suggest that
mGluR1c is present at the cell surface of CHO-K1 cells as a
dimer, which is the target of agonist mediated phosphoryla-
tion. The time course of the phosphorylation of the receptor
correlates with its desensitization kinetics and the inhibition of
protein kinase C causes only a partial reversal of desensitiza-
tion indicating that other kinases may be involved in this
process.
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